Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
Contribution of the oligodendrocyte lineage to CNS repair and neurodegenerative pathologies.
Top ten research priorities for spinal cord injury: the methodology and results of a British priority setting partnership.
PhIP-Seq characterization of autoantibodies from patients with multiple sclerosis, type 1 diabetes and rheumatoid arthritis.
Novantrone (mitoxantrone HCl) Injection February 2009
Antioxidant properties of the triaminopyridine, flupirtine.
Paraoxonase 1 activity in multiple sclerosis patients during mitoxantrone therapy.
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
Protective effects of monomethyl fumarate at the inflamed blood-brain barrier.
Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.
Pharmacodynamics of Dimethyl Fumarate are Tissue-specific and Involve NRF2-dependent and -independent Mechanisms.
Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration.
Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS.
Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol.
Monoclonal antibodies in MS: mechanisms of action.
Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis.
Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.
Biogen Idec submits application to FDA for approval of PLEGRIDY™ (peginterferon beta-1a) in multiple sclerosis
Spectrum of nontraumatic myelopathies in Ethiopian patients: hospital-based retrospective study.
Anti-JCV antibody levels in serum or plasma further define risk of natalizumab-associated PML.
Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders.
Teva Announces U.S. Supreme Court Decision to Reverse Federal Circuit Court’s Judgment on COPAXONE® 20 mg/mL Case and Remand for Further Review
Adaptive myelination from fish to man.

Pages